129 related articles for article (PubMed ID: 29367763)
1. Network analysis of SRC-1 reveals a novel transcription factor hub which regulates endocrine resistant breast cancer.
Browne AL; Charmsaz S; Varešlija D; Fagan A; Cosgrove N; Cocchiglia S; Purcell S; Ward E; Bane F; Hudson L; Hill AD; Carroll JS; Redmond AM; Young LS
Oncogene; 2018 Apr; 37(15):2008-2021. PubMed ID: 29367763
[TBL] [Abstract][Full Text] [Related]
2. Genomic interaction between ER and HMGB2 identifies DDX18 as a novel driver of endocrine resistance in breast cancer cells.
Redmond AM; Byrne C; Bane FT; Brown GD; Tibbitts P; O'Brien K; Hill AD; Carroll JS; Young LS
Oncogene; 2015 Jul; 34(29):3871-80. PubMed ID: 25284587
[TBL] [Abstract][Full Text] [Related]
3. Interaction of developmental transcription factor HOXC11 with steroid receptor coactivator SRC-1 mediates resistance to endocrine therapy in breast cancer [corrected].
McIlroy M; McCartan D; Early S; O Gaora P; Pennington S; Hill AD; Young LS
Cancer Res; 2010 Feb; 70(4):1585-94. PubMed ID: 20145129
[TBL] [Abstract][Full Text] [Related]
4. Global gene repression by the steroid receptor coactivator SRC-1 promotes oncogenesis.
Walsh CA; Bolger JC; Byrne C; Cocchiglia S; Hao Y; Fagan A; Qin L; Cahalin A; McCartan D; McIlroy M; O'Gaora P; Xu J; Hill AD; Young LS
Cancer Res; 2014 May; 74(9):2533-44. PubMed ID: 24648347
[TBL] [Abstract][Full Text] [Related]
5. IFITM1 suppression blocks proliferation and invasion of aromatase inhibitor-resistant breast cancer in vivo by JAK/STAT-mediated induction of p21.
Lui AJ; Geanes ES; Ogony J; Behbod F; Marquess J; Valdez K; Jewell W; Tawfik O; Lewis-Wambi J
Cancer Lett; 2017 Jul; 399():29-43. PubMed ID: 28411130
[TBL] [Abstract][Full Text] [Related]
6. Epigenome-wide SRC-1-Mediated Gene Silencing Represses Cellular Differentiation in Advanced Breast Cancer.
Ward E; Varešlija D; Charmsaz S; Fagan A; Browne AL; Cosgrove N; Cocchiglia S; Purcell SP; Hudson L; Das S; O'Connor D; O'Halloran PJ; Sims AH; Hill AD; Young LS
Clin Cancer Res; 2018 Aug; 24(15):3692-3703. PubMed ID: 29567811
[No Abstract] [Full Text] [Related]
7. Global characterization of the SRC-1 transcriptome identifies ADAM22 as an ER-independent mediator of endocrine-resistant breast cancer.
McCartan D; Bolger JC; Fagan A; Byrne C; Hao Y; Qin L; McIlroy M; Xu J; Hill AD; Gaora PÓ; Young LS
Cancer Res; 2012 Jan; 72(1):220-9. PubMed ID: 22072566
[TBL] [Abstract][Full Text] [Related]
8. Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures.
Kabos P; Finlay-Schultz J; Li C; Kline E; Finlayson C; Wisell J; Manuel CA; Edgerton SM; Harrell JC; Elias A; Sartorius CA
Breast Cancer Res Treat; 2012 Sep; 135(2):415-32. PubMed ID: 22821401
[TBL] [Abstract][Full Text] [Related]
9. Loss of pigment epithelium-derived factor: a novel mechanism for the development of endocrine resistance in breast cancer.
Jan R; Huang M; Lewis-Wambi J
Breast Cancer Res; 2012 Nov; 14(6):R146. PubMed ID: 23151593
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine-resistant Breast Cancer.
Wang X; Veeraraghavan J; Liu CC; Cao X; Qin L; Kim JA; Tan Y; Loo SK; Hu Y; Lin L; Lee S; Shea MJ; Mitchell T; Li S; Ellis MJ; Hilsenbeck SG; Schiff R; Wang XS
Clin Cancer Res; 2021 May; 27(9):2648-2662. PubMed ID: 33542078
[TBL] [Abstract][Full Text] [Related]
11. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
[TBL] [Abstract][Full Text] [Related]
12. S100β as a serum marker in endocrine resistant breast cancer.
Charmsaz S; Hughes É; Bane FT; Tibbitts P; McIlroy M; Byrne C; Cocchiglia S; McBryan J; Hennessy BT; Dwyer RM; Kerin MJ; Hill AD; Young LS
BMC Med; 2017 Apr; 15(1):79. PubMed ID: 28399921
[TBL] [Abstract][Full Text] [Related]
13. Transcriptomic Profiling of Sequential Tumors from Breast Cancer Patients Provides a Global View of Metastatic Expression Changes Following Endocrine Therapy.
McBryan J; Fagan A; McCartan D; Bane FT; Varešlija D; Cocchiglia S; Byrne C; Bolger J; McIlroy M; Hudson L; Tibbitts P; Gaora PÓ; Hill AD; Young LS
Clin Cancer Res; 2015 Dec; 21(23):5371-9. PubMed ID: 26240272
[TBL] [Abstract][Full Text] [Related]
14. Tamoxifen-induced ER-alpha-SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence.
Mc Ilroy M; Fleming FJ; Buggy Y; Hill AD; Young LS
Endocr Relat Cancer; 2006 Dec; 13(4):1135-45. PubMed ID: 17158759
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
[TBL] [Abstract][Full Text] [Related]
16. Reversal of endocrine resistance in breast cancer: interrelationships among 14-3-3ζ, FOXM1, and a gene signature associated with mitosis.
Bergamaschi A; Christensen BL; Katzenellenbogen BS
Breast Cancer Res; 2011 Jun; 13(3):R70. PubMed ID: 21707964
[TBL] [Abstract][Full Text] [Related]
17. Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.
Guest SK; Ribas R; Pancholi S; Nikitorowicz-Buniak J; Simigdala N; Dowsett M; Johnston SR; Martin LA
PLoS One; 2016; 11(6):e0157397. PubMed ID: 27308830
[TBL] [Abstract][Full Text] [Related]
18. Transcriptional regulation prediction of antiestrogen resistance in breast cancer based on RNA polymerase II binding data.
Zhang D; Wang G; Wang Y
BMC Bioinformatics; 2014; 15 Suppl 2(Suppl 2):S10. PubMed ID: 24564526
[TBL] [Abstract][Full Text] [Related]
19. Combinatorial targeting of a chromatin complex comprising Dot1L, menin and the tyrosine kinase BAZ1B reveals a new therapeutic vulnerability of endocrine therapy-resistant breast cancer.
Salvati A; Melone V; Sellitto A; Rizzo F; Tarallo R; Nyman TA; Giurato G; Nassa G; Weisz A
Breast Cancer Res; 2022 Jul; 24(1):52. PubMed ID: 35850772
[TBL] [Abstract][Full Text] [Related]
20. A miR-26a/E2F7 feedback loop contributes to tamoxifen resistance in ER-positive breast cancer.
Liu J; Li X; Wang M; Xiao G; Yang G; Wang H; Li Y; Sun X; Qin S; Du N; Ren H; Pang Y
Int J Oncol; 2018 Oct; 53(4):1601-1612. PubMed ID: 30066905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
